Senior Principal at PRMA Consulting Emily Coriale discusses how value assessments put forth by the Institute for Clinical and Economic Review (ICER), among other organizations, are gaining influence. Value Assessment Frameworks (VAFs) are used by many payers in their decision-making, especially when it comes to costly drugs. Although some organizations choose to ignore VAFs, Coriale warns against such a stance.
Coriale remarks, “Payers have decided they need to use VAFs as a tool – a source of unbiased, transparent, third-party information on drugs, providing information that goes beyond journal studies, reviews, and the usual manufacturer perspectives,” adding, “They’re pivoting towards value for money (cost-effectiveness) rather than their previous laser-like focus on the clinical benefits, safety, and efficacy of a drug.” Read more here.
(Source: Emily Coriale, PRMA Consulting, 10/21)